The decomposition of dead bodies is not the most aesthetically pleasing area of science to study, but for Professor Shari Forbes, it is by far the most interesting. [ + ]

For the biotechnology industry and for AusBiotech, the past year has been another action-packed period in policy terms, as well as the year the Australian biotech industry was ranked fourth in the world. [ + ]

US researchers have uncovered a 'pre-malignant' state in the blood that significantly increases the likelihood that an individual will develop blood cancers such as leukaemia, lymphoma or myelodysplastic syndrome. [ + ]

Cochlear has announced that seasoned executives Alison Deans and Glen Boreham will take on non-executive director roles starting from next year. [ + ]

GI Dynamics (ASX:GID) has revealed a restructuring plan involving cutting 10% of its workforce, including CFO Robert Crane. [ + ]

CSL (ASX:CSL), Hospira and GlaxoSmithKline have partnered with META and the University of Melbourne for a project aimed at improving manufacturing efficiency at Australian sites. [ + ]

Rhinomed (ASX:RNO) has won approval from key regulators for Mute, a medical device for snoring and sleep breathing, and published top-line data from a trial of the product in snorers. [ + ]

When scientists in the 17th century studied living organisms under an optical microscope for the first time, a new world opened up before their eyes. However, optical microscopy was limited by a physical restriction as to what size structures it was possible to resolve. Now, super-resolved fluorescence microscopy has bypassed this limitation.

Japanese researchers have successfully generated a kidney-like structure from just a single cell, thus making a huge leap forward in organ regeneration research. [ + ]

Professor Andrew Holmes reflects on the role serendipitous discovery has played in his successful research career as an organic chemist and how he is now stepping into the role as President of the Australian Academy of Science. [ + ]

Imugene has announced plans to divest its drug delivery platform linguet and revealed more promising preclinical data from its HER-Vaxx immuno-oncology program. [ + ]

Circadian Technologies (ASX:CIR) has raised $17.4m through a placement and share purchase plan, and plans to use the proceeds to take OPT-302 into the clinic in wet AMD. [ + ]

GI Dynamics (ASX:GID) has received the all-clear to resume shipments of its EnBobarrier obesity and diabetes therapy in the EU following a two-month suspension. [ + ]

Genetic Technologies (ASX:GTG) has announced the resignation of CEO Alison Mew, and has secured shareholder approval to change its name to Phenogen Sciences. [ + ]

EY has released its annual medical technology report for 2014 - 'Pulse of the industry: differentiating differently'. [ + ]